VASH1: A Protein Interaction and Potential Drug Target for Neurological Disorders

Target Name: VASH1

NCBI ID: G22846

VASH1

VASH1: A Protein Interaction and Potential Drug Target for Neurological Disorders

VASH1 (TTCP 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and gastrointestinal tract. It is a member of the TTCP family, which includes several similar proteins that are involved in various cellular processes, including cell signaling and membrane transport.

One of the unique features of VASH1 is its ability to interact with several different proteins, including the neurotransmitter acetylcholine, which is involved in memory and cognitive function. This interaction suggests that VASH1 may be involved in the regulation of neurotransmitter signaling, which could make it a potential drug target or biomarker for various neurological and psychiatric disorders.

In addition to its potential role in neurotransmission, VASH1 has also been shown to play a role in regulating inflammation in the body. This is important because many neurological and psychiatric disorders are associated with inflammation, and targeting inflammation could be a potential approach to treating these conditions.

VASH1 has also been shown to be involved in the regulation of cell signaling processes, which are important for the development and maintenance of tissues and organs. This suggests that VASH1 may be involved in the regulation of cell proliferation, differentiation, and survival, which could be important for the development of cancer.

Another potential aspect of VASH1's role in the body is its involvement in the regulation of the immune system. This is important because the immune system plays a critical role in protecting the body against infection and disease, and disorders that affect the immune system, such as allergies and autoimmune diseases, can be devastating.

In conclusion, VASH1 is a protein that has been shown to interact with several different proteins, including the neurotransmitter acetylcholine, which suggests that it may be involved in the regulation of neurotransmission. In addition, VASH1 has also been shown to play a role in regulating inflammation, cell signaling processes, and the immune system. These properties make it a potential drug target or biomarker for various neurological and psychiatric disorders. Further research is needed to fully understand the role of VASH1 in the body, and to determine if it may be a useful target for the development of new treatments for these conditions.

Protein Name: Vasohibin 1

Functions: Tyrosine carboxypeptidase that removes the C-terminal tyrosine residue of alpha-tubulin, thereby regulating microtubule dynamics and function (PubMed:29146869, PubMed:31270470, PubMed:31235910, PubMed:31171830, PubMed:31235911). Critical for spindle function and accurate chromosome segregation during mitosis since microtuble detyronisation regulates mitotic spindle length and postioning (PubMed:31171830). Acts as an angiogenesis inhibitor: inhibits migration, proliferation and network formation by endothelial cells as well as angiogenesis (PubMed:15467828, PubMed:16488400, PubMed:16707096, PubMed:19204325). This inhibitory effect is selective to endothelial cells as it does not affect the migration of smooth muscle cells or fibroblasts (PubMed:15467828, PubMed:16488400, PubMed:16707096)

The "VASH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VASH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets